CN109248269A - A kind of traditional Chinese medicine for outer use for treating hyperplasia of mammary glands - Google Patents
A kind of traditional Chinese medicine for outer use for treating hyperplasia of mammary glands Download PDFInfo
- Publication number
- CN109248269A CN109248269A CN201811269512.2A CN201811269512A CN109248269A CN 109248269 A CN109248269 A CN 109248269A CN 201811269512 A CN201811269512 A CN 201811269512A CN 109248269 A CN109248269 A CN 109248269A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- hyperplasia
- outer use
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/808—Scrophularia (figwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8884—Arisaema, e.g. Jack in the pulpit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of traditional Chinese medicine for outer use for treating hyperplasia of mammary glands, the traditional Chinese medicine for outer use is grouped as by each group of following parts by weight: 20-40 parts of tangerine seed, 10-30 parts of fritillaria thunbergii, 10-30 parts of radix scrophulariae, 20-40 parts of oyster, 8-16 parts of olibanum, 8-16 parts of myrrh, 5-15 parts of corydalis tuber, 4-8 parts of cortex cinnamomi, 8-16 parts of arisaema cum bile, 6-12 parts of bletilla.Simple production process of the present invention, production cost is low, implementation is strong, is easy to large-scale industrial production；The Chinese materia medica preparation being compounded to form by tangerine seed, fritillaria thunbergii, radix scrophulariae, oyster, olibanum, myrrh, corydalis tuber, cortex cinnamomi, arisaema cum bile, bletilla etc. has significant curative effect for treatment Cystic hyperplasia breast, and therapeutic effect is significant, Small side effects；It is easy to use simultaneously, and can preferably guarantee medicine stability and effect.The present invention has obtained reasonable, stable preparation proportion, has had significant economic and social benefit according to the physicochemical property of each flavour of a drug ingredient and the result of study of pharmacological action.
Description
Technical field
The present invention relates to the field of Chinese medicines, the traditional Chinese medicine for outer use of specifically a kind for the treatment of hyperplasia of mammary glands.
Background technique
Hyperplasia of mammary glands is young women common disease, is using periodical lump in breast, distending pain as the cream of clinical characters
Gland non-inflammatory disease.It is because ovarian dysfunction causes female to swash it is now recognized that its morbidity is related with endocrine function imbalance
Plain horizontal excessively high, common with caused one kind out of proportion of lutern benign breast lesions, with mammary gland alveolus and conduit end
The epithelial cell hyperplasia of section is major pathologic features.This disease names various confusion, such as Cystic hyperplasia breast, capsule mammary gland
Breast lesion classification naming is mammary dysplasia by disease, cystic hyperplasia of breast, fibrocystic disease etc., WHO.
At this stage, for hyperplasia of mammary glands, the main method for using antagonising oestrogen, representing drug includes tamoxifen
Sweet smell, methyl testosterone etc., but endometrium can when used for a long time reduced the sensibility of estrogen, it is also easier to occur bad anti-
It answers；A kind of traditional Chinese medicine for outer use for treating hyperplasia of mammary glands disclosed by the invention is traditional Chinese medicine compound preparation, have mass dissipating and swelling eliminating,
Blood-activating analgetic and other effects, pharmaceutical research show that it has obvious inhibiting effect to mammary gland alveolus and catheter hyperplasia.
For above situation, we observe a kind of traditional Chinese medicine for outer use joint tamoxifen for treating hyperplasia of mammary glands
Fragrant, methyl testosterone treatment hyperplasia of mammary glands Clinical efficacy and safety, and a kind of hyperplasia of mammary glands for the treatment of is provided
Traditional Chinese medicine for outer use.
Summary of the invention
The purpose of the present invention is to provide a kind of traditional Chinese medicine for outer use for treating hyperplasia of mammary glands, to solve the prior art
The problems in.
To achieve the above object, the invention provides the following technical scheme: a kind of external application Chinese medicine for treating hyperplasia of mammary glands
Preparation, the traditional Chinese medicine for outer use are grouped as by each group of following parts by weight: 20-40 parts of tangerine seed, 10-30 parts of fritillaria thunbergii, profound
Join 10-30 parts, 20-40 parts of oyster, 8-16 parts of olibanum, 8-16 parts of myrrh, 5-15 parts of corydalis tuber, 4-8 parts of cortex cinnamomi, arisaema cum bile 8-16
Part, 6-12 parts of bletilla.
Further, the traditional Chinese medicine for outer use is grouped as by each group of following parts by weight: 25-35 parts of tangerine seed, bulb of thunberg fritillary
15-25 parts female, 15-25 parts of radix scrophulariae, 25-35 parts of oyster, 10-14 parts of olibanum, 10-14 parts of myrrh, 8-12 parts of corydalis tuber, cortex cinnamomi 5-
7 parts, 10-14 parts of arisaema cum bile, 8-10 parts of bletilla.
Further, the traditional Chinese medicine for outer use is grouped as by each group of following parts by weight: 30 parts of tangerine seed, fritillaria thunbergii 20
Part, 20 parts of radix scrophulariae, 30 parts of oyster, 12 parts of olibanum, 12 parts of myrrh, 10 parts of corydalis tuber, 6 parts of cortex cinnamomi, 12 parts of arisaema cum bile, 9 parts of bletilla.
Further, the traditional Chinese medicine for outer use dosage form are as follows: spray, pulvis, powder, ointment, suppository, emplastrum and
Gauze agent.
Drug pharmacology in the present invention are as follows:
Tangerine seed, nature and flavor: bitter, mild-natured.Channel tropism: return liver and kidney channel.Major function: having regulating qi-flowing for relieving pain, Sweeling-eliminating medicine powder malicious, scattered
The effect of knot analgesic；For treating hernia, testiclar gall, acute mastitis, pain in the loins, colicky pain of bladder.
Fritillaria thunbergii, nature and flavor: bitter, cold.Channel tropism: return lung, the heart channel of Hang-Shaoyin.Major function: preventing phlegm from forming and stopping coughing, heat-clearing dissipating bind；For treating
Cough with lung heat, dry cough due to yin deficiency, carbuncle swells, scrofula.
Radix scrophulariae, nature and flavor: sweet in flavor, bitter, salty；Cold nature.Channel tropism: return lung, stomach, kidney channel.Major function: clearing heat and cooling blood, purging intense heat
Removing toxic substances, enriching yin；It joins the army for treating warm heresy, the pericardium that invaginates, febrile virulent maculae, consumption of YIN caused by febrile disease, the deep red polydipsia of tongue, Tianjin hinder constipation, hectic fever due to yin
Overstrain cough, hot eyes, pharyngalgia, scrofula, diphtheria, carbuncle sore tumefacting virus.
Oyster, nature and flavor: salty, slightly cold.Channel tropism: return liver, gallbladder, kidney channel.Major function: transquilization with heavy material, checking exuberance of yang and tonifying yin, softening hard masses dissipate
Knot；For treating insomnia of palpitating with fear, dizziness and tinnitus, scrofula subcutaneous nodule, abdominal mass lump in the abdomen.
Olibanum, nature and flavor: pungent, bitter, temperature.Channel tropism: return heart, liver, the spleen channel.Major function: blood-activating and qi-promoting analgesic, detumescence and promoting granulation；
For treating chest impediment and cardialgia, gastral cavity pain, dysmenorrhea menostasis, postpartum stasis, abdominal mass abdominal pain, rheumatic arthralgia.
Myrrh, nature and flavor: it is pungent, bitter, it puts down.Channel tropism: return heart, liver, the spleen channel.Major function: scattered stasis pain, detumescence and promoting granulation；For
Treat chest impediment and cardialgia, gastral cavity pain, dysmenorrhea menostasis, postpartum stasis, abdominal mass and abdominal pain, rheumatic arthralgia.
Corydalis tuber is Papaveraceae Corydalis herbaceos perennial, is used as medicine with stem tuber；Nature and flavor: acrid, bitter, warm.Channel tropism: return
The heart, spleen, liver, lung channel.Major function: having the function of thering is promoting blood circulation to remove blood stasis, regulating qi-flowing for relieving pain；For treating stomachache, dysmenorrhea, bruise damage
Wound.
Cortex cinnamomi, nature and flavor: pungent, sweet, hot.Channel tropism: return kidney, spleen, the heart, Liver Channel.Major function: mends fire supporing yang, eliminating cold to stop pain, temperature
Qualcomm meridian；For treating the insufficiency of the kidney yang, positive fistula palace cold, the cold abdomen of stomach duct and abdomen, arthritis pain in the loins, cold hernia stomachache, cold blood stasis, menostasis pain
Through, chest impediment and cardialgia.
Arisaema cum bile, nature and flavor: cool, bitter, micro-pungent.Channel tropism: return lung, liver, the spleen channel.Major function: clear property thermalization phlegm, relieve the wind syndrome are fixed
It is frightened；For treating stroke and phlegm confusing heart, infantile convulsion epilepsy, convulsive seizure due to phlegm-fire asthma are coughed, phlegm-accumulating vertigo etc..
Bletilla, the dry tuber of orchid bletilla.Nature and flavor: it is bitter, sweet, puckery, it is slightly cold.Channel tropism: return lung, liver, stomach meridian.Function
The major functions: astringing to arrest bleeding, detumescence and promoting granulation；For treating hemoptysis, haematemesis, traumatic hemorrhage, sore swollen toxin, chapped skin.
Compared with prior art, the beneficial effects of the present invention are:
The present invention has mass dissipating and swelling eliminating, blood-activating analgetic and other effects, and clinical research shows that the compound preparation can treat mammary gland
Lobular hyperplasia, while pharmaceutical research shows that it has obvious inhibiting effect to mammary gland alveolus and catheter hyperplasia, can reduce serum
Estrogen level and breast tissue sex hormone receptor positive gland cell number effectively mitigate hyperplasia of mammary lobule reason variation.
Compared with the existing technology, simple production process, production cost are low, implementation is strong by the present invention, are easy to large-scale industry
Metaplasia produces；It is compounded to form by tangerine seed, fritillaria thunbergii, radix scrophulariae, oyster, olibanum, myrrh, corydalis tuber, cortex cinnamomi, arisaema cum bile, bletilla etc.
Chinese materia medica preparation has significant curative effect for treatment Cystic hyperplasia breast, and therapeutic effect is significant, Small side effects；User simultaneously
Just, and it can preferably guarantee medicine stability and effect.
The present invention has obtained rationally, surely according to the physicochemical property of each flavour of a drug ingredient and the result of study of pharmacological action
Fixed preparation proportion, using technical solution of the present invention, the drug quality prepared is stably and controllable, curative effect and existing market sell agent
Type has significant economic and social benefit compared to significantly improving.
Detailed description of the invention
In order that the present invention can be more clearly and readily understood, right below according to specific embodiment and in conjunction with attached drawing
The present invention is described in further detail.
Fig. 1 is a kind of shape of the micro- sem observation breast tissue for the traditional Chinese medicine for outer use for treating hyperplasia of mammary glands of the present invention
State illustrates (original magnification, 200 times)；
Fig. 2 is a kind of shape of the micro- sem observation breast tissue for the traditional Chinese medicine for outer use for treating hyperplasia of mammary glands of the present invention
State illustrates (original magnification, 100 times).
In figure: normal group of A-；B- model group；C- stosterone group；D- Chinese materia medica preparation high dose group；E- Chinese materia medica preparation middle dosage
Group；F- Chinese materia medica preparation low dose group.
Specific embodiment
The following is a clear and complete description of the technical scheme in the embodiments of the invention, it is clear that described embodiment
Only a part of the embodiment of the present invention, instead of all the embodiments.Based on the embodiments of the present invention, the common skill in this field
Art personnel every other embodiment obtained without making creative work belongs to the model that the present invention protects
It encloses.
Embodiment 1:
A kind of traditional Chinese medicine for outer use for treating hyperplasia of mammary glands, is grouped as by each group of following parts by weight: tangerine seed 20
Part, 10 parts of fritillaria thunbergii, 10 parts of radix scrophulariae, 20 parts of oyster, 8 parts of olibanum, 8 parts of myrrh, 5 parts of corydalis tuber, 4 parts of cortex cinnamomi, 8 parts of arisaema cum bile,
6 parts of bletilla.
Embodiment 2:
A kind of traditional Chinese medicine for outer use for treating hyperplasia of mammary glands, is grouped as by each group of following parts by weight: tangerine seed 40
Part, 30 parts of fritillaria thunbergii, 30 parts of radix scrophulariae, 40 parts of oyster, 16 parts of olibanum, 16 parts of myrrh, 15 parts of corydalis tuber, 8 parts of cortex cinnamomi, arisaema cum bile 16
Part, 12 parts of bletilla.
Embodiment 3:
A kind of traditional Chinese medicine for outer use for treating hyperplasia of mammary glands, is grouped as by each group of following parts by weight: tangerine seed 25
Part, 15 parts of fritillaria thunbergii, 20 parts of radix scrophulariae, 25 parts of oyster, 14 parts of olibanum, 12 parts of myrrh, 10 parts of corydalis tuber, 7 parts of cortex cinnamomi, arisaema cum bile 12
Part, 8 parts of bletilla.
Embodiment 4:
A kind of traditional Chinese medicine for outer use for treating hyperplasia of mammary glands, is grouped as by each group of following parts by weight: tangerine seed 30
Part, 20 parts of fritillaria thunbergii, 20 parts of radix scrophulariae, 30 parts of oyster, 12 parts of olibanum, 12 parts of myrrh, 10 parts of corydalis tuber, 6 parts of cortex cinnamomi, arisaema cum bile 12
Part, 9 parts of bletilla.
Clinical observation:
1, general information: be included in standard: according to Standards for Diagnosis and Curative Effect of Chinese Medical Symptom, unilateral or bilateral breast can be laid one's hand on and 1
Piece or more pieces of flat lumps, boundary owes clear, with surrounding tissue adhesion；It is swollen often to there is the breast occurred with menstrual cycle property
Block, distending pain；The inspections such as piece B ultrasound, infrared heat image are taken the photograph using molybdenum target, mammogram and assist diagnosis, do histopathology when necessary
Inspection is diagnosed as the proliferation of mammary gland.Exclusion criteria: the benign made a definite diagnosis, malignant tumour；Physiological breast pain；The gestational period or lactation
Phase women；6 months inscribed to have received hormone therapy or has taken contraceptive；Merge other systems serious disease.
2, case selection and grouping: the hyperplasia of mammary glands patient that hospital accepts for medical treatment in June, 2016 in January, 2017 is chosen
200, two groups of patient's general information compare, and no significant difference is women, is randomly divided into 2 groups, be divided into control group and
Observation group, each 100, patient signs informed consent form, and research is ratified through hospital's Medical Ethics Committee.
3, therapeutic process: control group patient takes orally Tamoxifen citrate tablet, and 2 times a day, 1 tablet once；It is combined first simultaneously
Testosterone piece, one time a day, 2 tablets once.Two kinds of drugs, which took orally in premenstrual 15 days of the moon to menstrual onset day, to be stopped, and is taken altogether 3 months.
Observation group patient is applied with the traditional Chinese medicine for outer use of hyperplasia of mammary glands, once a day, the course for the treatment of on the basis of control group therapeutic scheme
It is identical as control group.
The wherein drug of Tamoxifen citrate tablet selection ShangHai Fudan Fuhua Pharmaceutical Co., Ltd, national drug standard
H31021545, specification are every 10mg, and methyltestosterone tablets select the drug of HARBIN PHARMACEUTICAL GROUP CO., LTD. General Pharm. Factory, national drug standard
H23020909, specification are every 5mg.
4, observation index and curative effect determinate standard
B ultrasound observes patient's hyperplasia of mammary glands lump diameter change situation；Separately commented by pain visual imitation assessment (VAS)
Valence patient breast lump, distending pain situation of change；Using chemoluminescence method, pretherapy and post-treatment two groups of patients serum's prolactin are detected
(PRL), the situation of change of the sex hormone such as estradiol (E2) and progesterone (P)；It observes and counts patient treatment procedure's Chinese medicine condition pass
A situation arises for adverse reaction.
Therapeutic evaluation is commented referring to the cyclomastopathy curative effect that Chinese mastosis Professional Committee of the association of traditional Chinese medicine in 2002 works out
Price card is quasi-:
Cure: lump in breast and pain disappear, and stop treatment and do not recur for 3 months；
Effective: tumor regression (diameter) is greater than 1/2, and mammary gland pain disappears；
Effective: lump in breast subsides (diameter) less than 1/2 and mammary gland pain mitigates；
Invalid: lump in breast diameter or swelling and pain symptom are unchanged；
Former three adds up to total effective.
5, statistical procedures
It is analyzed using SPSS19.0 statistics software, measurement data is indicated with X ± s, and row t is examined；Enumeration data is with percentage
Rate expression, row χ2It examines.P < 0.05 is that difference is statistically significant.
6, result
It is obtained medical treatment data according to above-mentioned steps, data are as shown in the table:
1: two group of patient clinical curative effect of table compares [(example) %, n=100]
2: two groups of patient clinical curative effects of table compare [(example) %, n=100]
Note: with this group before treatment,#P < 0.05；Compared with after control group treatment,*P < 0.05.
3: two groups of sex hormone's levels of table compare (X ± s, μ g/L, n=100)
Note: with this group before treatment,#P < 0.05；Compared with after control group treatment,*P < 0.05.
Conclusion: after the clinical efficacy course for the treatment of, observation group's patient's total effective rate is significantly higher than control group；Lump in breast and swollen
After the treatment of pain situation, two groups of patient's chest Tumor sizes and swollen breasts VAS scoring are remarkably decreased (P < 0.05), and are observed
Group patient's chest mass reduction degree is significantly greater than control group；After traditional Chinese medicine for outer use treatment, two groups of patients PRL and E2 are relatively controlled
It is decreased obviously before treatment, and P is increased before relatively treating, difference is statistically significant (P < 0.05).
Influence research of the traditional Chinese medicine for outer use to experimental rat hyperplasia of mammary glands model:
1, material and instrument
The traditional Chinese medicine for outer use of hyperplasia of mammary glands；The non-pregnant rat of animals female, 25 week old, weight (180 ± 25) g；
Instrument and the automatic Enzyme Immunoassay Analyzer of reagent, radioimmunoanalyzer, freezing microtome, microscope and micrometering ruler, benzene first
Sour estradiol suspension,sterile, progesterone injection, 3H- progesterone analytical reagent, estradiol enzyme labeled analysis reagent, breast tissue swash
Plain receptor (estrogen receptor, progesterone receptor) marks staining reagent；Remaining reagent is analytical reagents.
2, method:
1. rat mammary gland lobular hyperplasia pathological model modeling: taking rat several, benzoic acid female two is subcutaneously injected in daily armpit
Alcohol 0.5mgkg-1, continuous 25 days, change note progesterone 1mgkg later-1, continuous 5 days；Next day rejects breast and increases after drug withdrawal
The rat of unobvious (substrate < 3mm) then randomly selects 10 rats and puts to death, and the breast that every selection one significantly increases is made
Histopathological examination increases expansion with mammary gland alveolus, lumen of gland hydrops, gland cell increase loose, glandular tissue estrogen receptor sun
It is that successful mammary gland is small that gonadal cell and progesterone receptor positive gland cell, which account for 20% or more person of microscopic field whole gland cell,
Leaf preneoplastic lesions.
It is that this batch is big that the breast tissue pathological examination of 10 rats, which has 8 or more rat breasts to meet this pathological change,
The success of mouse hyperplasia of mammary glands model.It starts to be not later than after deactivated progesterone 3 for subsequent experimental.
2. influence experiment of the Chinese materia medica preparation to rat mammary gland lobular hyperplasia model: taking female qualified non-pregnant rat 10, often
Rule raising, is not administered, makees normal group；Take hyperplasia of mammary glands rat model 50, be randomly divided into model group, stosterone group, in
High, medium and low three dosage groups of medicine preparation, every group 10；Each group rat model is individually lain on the back fixation, unhairing 2cm at ventral breast
× 2cm, with being adsorbed at the apparent lesion breast of a hyperplasia of mammary glands after diameter 1.5cm sucker powder charge 2mL, then sucker
The extraction of interior air, imposes negative pressure in sucker, and medical fluid and breast surface skin close contact is kept withdrawal and to release solid after 6 hours
It is fixed；Model group gives 2.5% testosterone propionate injection, high, normal, basic three dosage groups of Chinese materia medica preparation to physiological saline, stosterone group
Respectively 15gmL-1、10g·mL-1And 5gmL-1Chinese materia medica preparation；So it is fixed on a breast part repetitively administered, 1
Times/day, continuous 30 days；Next day puts to death whole rats after administration, takes blood examination to survey serum Estrogen and progestin horizontal；Take mammary gland group
It knits conventional section and observes its tissue morphology, select the maximum acinus in the garden visual field Zhong, measure alveolar lumen diameter and gland cell height；
Mammary gland frozen section is taken, is marked and is dyed with breast tissue sex hormone receptor (estrogen receptor, progesterone receptor), 100-1000 times
Microexamination selects 10 gland cell profiles using the person that has brown yellow granule in cell paddle or core as sex hormone receptor positive cell
It shows that clear, born of the same parents' paddle or nuclear particle colour the good visual field, calculates Estrogen and progesterone receptors positive cell percentage in breast tissue
Rate；Every Index for examination is counted, compared with model group；With the significance of difference between t value method check groups.
3, result
Data are obtained according to above-mentioned steps, as shown in the table:
Table 4: influence (x ± s) of the Chinese materia medica preparation to hyperplasia of mammary glands rat model serum Estrogen and progestin level
Note: compared with model group,*P < 0.05, n=10
Table 5: influence (x ± s) of the newborn health tincture to hyperplasia of mammary glands rat model breast tissue and cell
Conclusion: Chinese materia medica preparation senior middle school low dose group and stosterone group blood are shown in next day after administration, Serum Sex Hormones inspection
Clear estrogen level is lower than model group, and difference has conspicuousness, and each group progesterone level shows Chinese materia medica preparation and testis without significant difference
Ball ketone has an impact to the activity of rat model sexual gland or gonad axis.
Histopathological examination (such as Fig. 1) is shown in that model group rats breast increases, and lobule of mammary gland increases, acinus increase expansion,
Lumen of gland hydrops, gland cell increase loose, glandular tissue Estrogen and progesterone receptors positive gland cell and account for microscopic field whole gland cell 20%
More than, rat mammary gland lobular hyperplasia pathological change is not because deactivating induction sex hormone due to spontaneous recovery during showing medicine-feeding test.
Histopathological examination (such as Fig. 2) is shown in mammary gland the robust proliferation for observing body of gland leaflet and leaflet, great Liang Fen after administration 30 days
It secretes, vascular arborization, lymphoplasmacytic and thick liquid cell；Chinese materia medica preparation senior middle school low dose group and stosterone group breast endite and acinus
Hyperplasia is reduced, and luminal sectetion and lymphocyte are reduced, and illustrates that mammary gland restores good, does not almost have in body of gland acinus and lobule of mammary gland
There is hyperplasia, only see seldom secretion and lymphocyte, while illustrating high, normal, basic three dosage groups of Chinese materia medica preparation to rat mammary gland
Lobular hyperplasia has certain therapeutic effect.
Chinese materia medica preparation senior middle school low dose group and stosterone group rat mammary gland alveolar lumen diameter, gland cell height, glandular tissue are female
Hormone receptor positive gland cell percentage and progesterone receptor positive gland cell percentage are respectively less than model group, and difference has conspicuousness
Meaning shows that Chinese materia medica preparation and stosterone have and mitigates hyperplasia of mammary glands effect.
It is obvious to a person skilled in the art that invention is not limited to the details of the above exemplary embodiments, Er Qie
In the case where without departing substantially from spirit or essential attributes of the invention, the present invention can be realized in other specific forms.Therefore, no matter
From the point of view of which point, the present embodiments are to be considered as illustrative and not restrictive, and the scope of the present invention is by appended power
Benefit requires rather than above description limits, it is intended that all by what is fallen within the meaning and scope of the equivalent elements of the claims
Variation is included within the present invention.Any reference signs in the claims should not be construed as limiting the involved claims.
Claims (4)
1. a kind of traditional Chinese medicine for outer use for treating hyperplasia of mammary glands, it is characterised in that: the traditional Chinese medicine for outer use is by following heavy
The each group of amount number is grouped as: 20-40 parts of tangerine seed, 10-30 parts of fritillaria thunbergii, 10-30 parts of radix scrophulariae, 20-40 parts of oyster, olibanum 8-16
Part, 8-16 parts of myrrh, 5-15 parts of corydalis tuber, 4-8 parts of cortex cinnamomi, 8-16 parts of arisaema cum bile, 6-12 parts of bletilla.
2. a kind of traditional Chinese medicine for outer use for treating hyperplasia of mammary glands according to claim 1, it is characterised in that: described outer
It is grouped as with Chinese materia medica preparation by each group of following parts by weight: 25-35 parts of tangerine seed, 15-25 parts of fritillaria thunbergii, 15-25 parts of radix scrophulariae, male
25-35 parts of oyster, 10-14 parts of olibanum, 10-14 parts of myrrh, 8-12 parts of corydalis tuber, 5-7 parts of cortex cinnamomi, 10-14 parts of arisaema cum bile, bletilla 8-
10 parts.
3. a kind of traditional Chinese medicine for outer use for treating hyperplasia of mammary glands according to claim 2, it is characterised in that: described outer
It is grouped as with Chinese materia medica preparation by each group of following parts by weight: 30 parts of tangerine seed, 20 parts of fritillaria thunbergii, 20 parts of radix scrophulariae, 30 parts of oyster, cream
Fragrant 12 parts, 12 parts of myrrh, 10 parts of corydalis tuber, 6 parts of cortex cinnamomi, 12 parts of arisaema cum bile, 9 parts of bletilla.
4. a kind of traditional Chinese medicine for outer use for treating hyperplasia of mammary glands described in any one of -3 according to claim 1, special
Sign is: the traditional Chinese medicine for outer use dosage form are as follows: spray, pulvis, powder, ointment, suppository, emplastrum and gauze agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811269512.2A CN109248269A (en) | 2018-10-29 | 2018-10-29 | A kind of traditional Chinese medicine for outer use for treating hyperplasia of mammary glands |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811269512.2A CN109248269A (en) | 2018-10-29 | 2018-10-29 | A kind of traditional Chinese medicine for outer use for treating hyperplasia of mammary glands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109248269A true CN109248269A (en) | 2019-01-22 |
Family
ID=65046793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811269512.2A Pending CN109248269A (en) | 2018-10-29 | 2018-10-29 | A kind of traditional Chinese medicine for outer use for treating hyperplasia of mammary glands |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109248269A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109806329A (en) * | 2019-04-12 | 2019-05-28 | 欧阳萍 | A kind of Chinese medicine composition, preparation method and application |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007210933A (en) * | 2006-02-09 | 2007-08-23 | Yoichiro Ebe | Therapeutic agent for hay fever by chinese drug recipe |
| CN102614457A (en) * | 2012-03-14 | 2012-08-01 | 安康正大制药有限公司 | Preparation method of breast recovering tablet |
| CN103961544A (en) * | 2013-01-25 | 2014-08-06 | 赵粉娥 | Medicine for treating breast diseases |
| CN104623561A (en) * | 2015-03-06 | 2015-05-20 | 刘静 | Traditional Chinese medicine for treating hyperplasia of mammary glands |
-
2018
- 2018-10-29 CN CN201811269512.2A patent/CN109248269A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007210933A (en) * | 2006-02-09 | 2007-08-23 | Yoichiro Ebe | Therapeutic agent for hay fever by chinese drug recipe |
| CN102614457A (en) * | 2012-03-14 | 2012-08-01 | 安康正大制药有限公司 | Preparation method of breast recovering tablet |
| CN103961544A (en) * | 2013-01-25 | 2014-08-06 | 赵粉娥 | Medicine for treating breast diseases |
| CN104623561A (en) * | 2015-03-06 | 2015-05-20 | 刘静 | Traditional Chinese medicine for treating hyperplasia of mammary glands |
Non-Patent Citations (3)
| Title |
|---|
| 张树刚等: "他莫昔芬与甲基睾丸素联合小金丸治疗乳腺小叶增生临床评价", 《中国药业》 * |
| 曾宪彪等: "乳康酊对实验性大鼠乳腺小叶增生模型的影响研究", 《时珍国医国药》 * |
| 汤小平等: "《百病中药外治大全》", 30 November 2016, 华中科技大学出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109806329A (en) * | 2019-04-12 | 2019-05-28 | 欧阳萍 | A kind of Chinese medicine composition, preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103316219A (en) | Traditional Chinese medicinal preparation for treating phthisis and preparation method thereof | |
| CN105412787A (en) | Medicine for treating postpartum irregular menstruation | |
| CN101455745A (en) | Medicine composition for treating hemorrhoids and preparation method thereof | |
| CN109248269A (en) | A kind of traditional Chinese medicine for outer use for treating hyperplasia of mammary glands | |
| CN111297910A (en) | Application of maggot in preparing medicine for preventing and treating hyperplasia of mammary glands | |
| CN104147180B (en) | Pharmaceutical composition for the treatment of immunologic thrombocytopenic purpura and preparation method thereof | |
| CN104324317B (en) | A kind of Chinese medicine composition and medical usage for treating fibroid | |
| CN105944020B (en) | Traditional Chinese medicine for treating ovarian function decline | |
| CN104645297B (en) | A kind of temperature palace helps pregnant Chinese medicine composition and its formulation preparation method | |
| CN104706919B (en) | A kind of pharmaceutical composition for the treatment of ulcer in body surface | |
| CN103191399A (en) | Traditional Chinese medicine composition for treating bronchial asthma in acute-outbreak period | |
| CN105770691A (en) | Medicinal preparation for treating cervical cancer and application thereof | |
| CN107213426B (en) | Chinese patent medicine for treating mammary gland diseases and preparation method thereof | |
| CN101698037B (en) | Medicine for treating uterine bleeding and preparation process thereof | |
| CN104491721A (en) | Traditional Chinese medicine for treating spleen and kidney yang deficiency type cervical cancer and preparation method thereof | |
| CN115581749B (en) | Traditional Chinese medicine composition for treating hyperplasia of mammary glands and preparation method thereof | |
| CN102716424A (en) | Breast nodule treatment medicine composition and preparation process and application thereof | |
| CN101361955B (en) | Traditional Chinese medicine combination for treating rheumatism | |
| CN106266500B (en) | A kind of Chinese medicine composition for treating the proliferation of mammary gland | |
| CN105770265A (en) | Medicinal preparation for treating esophageal carcinoma and application thereof | |
| CN105596687A (en) | Traditional Chinese medicine for treating perimenopausal syndrome | |
| CN105597020A (en) | Pharmaceutical composition for treating polycystic ovarian syndrome combined with mammary gland hyperplasia | |
| CN105535626A (en) | Traditional Chinese medicine for treating tuberculosis by combination with anti-tuberculosis western medicine | |
| CN105031499A (en) | Traditional Chinese medicine composition for treating duodenal ulcer | |
| CN104383467A (en) | Traditional Chinese medicine for treating liver-qi depression type cervical cancer and preparation method of traditional Chinese medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190122 |